Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

Matched clinical trials

  • Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium Czechia France Germany Greece Ireland +3
  • Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

    Not recruiting

    1 1 1 1
    Belgium Czechia France Germany Italy The Netherlands +3
  • Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

    Not recruiting

    1 1
    Belgium France Germany Italy The Netherlands Spain
  • Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy

    Not recruiting

    1 1 1
    Investigated diseases:
    France Germany Poland
  • Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

    Not recruiting

    1 1
    Belgium France Germany Greece Italy The Netherlands +2
  • Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy

    Not recruiting

    1 1 1
    Investigated drugs:
    Denmark France Germany Greece Italy Poland +1
  • Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

    Not recruiting

    1 1 1 1
    Austria Belgium Czechia France Germany Greece +4
  • Study on Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Urothelial Cancer

    Not recruiting

    1 1 1
    France
  • Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

    Not recruiting

    1 1 1 1
    Belgium Czechia Denmark France Germany Hungary +4
  • Study comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer

    Not recruiting

    1 1 1 1
    Portugal Spain